Vanda Pharmaceuticals (VNDA) Posts Earnings Results, Beats Expectations By $0.18 EPS

Vanda Pharmaceuticals (NASDAQ:VNDA) posted its earnings results on Wednesday. The biopharmaceutical company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18, Briefing.com reports. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. The firm had revenue of $49.13 million for the quarter, compared to the consensus estimate of $49.44 million. During the same period in the previous year, the firm posted ($0.03) EPS. The business’s quarterly revenue was up 18.9% on a year-over-year basis. Vanda Pharmaceuticals updated its FY 2018 guidance to EPS.

Shares of VNDA stock traded up $3.01 during trading hours on Thursday, reaching $23.46. 1,937,092 shares of the stock were exchanged, compared to its average volume of 689,217. Vanda Pharmaceuticals has a 12-month low of $11.90 and a 12-month high of $25.07. The stock has a market cap of $1.05 billion, a PE ratio of -67.03 and a beta of 1.06.

Several hedge funds have recently added to or reduced their stakes in VNDA. Trexquant Investment LP purchased a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $212,000. Hartford Investment Management Co. purchased a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at about $214,000. Meeder Asset Management Inc. boosted its position in Vanda Pharmaceuticals by 164.6% in the 3rd quarter. Meeder Asset Management Inc. now owns 11,417 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 7,102 shares during the period. NumerixS Investment Technologies Inc boosted its position in Vanda Pharmaceuticals by 92.9% in the 2nd quarter. NumerixS Investment Technologies Inc now owns 11,835 shares of the biopharmaceutical company’s stock valued at $227,000 after buying an additional 5,700 shares during the period. Finally, Piedmont Investment Advisors Inc. boosted its position in Vanda Pharmaceuticals by 1,255.3% in the 3rd quarter. Piedmont Investment Advisors Inc. now owns 12,089 shares of the biopharmaceutical company’s stock valued at $277,000 after buying an additional 11,197 shares during the period. 93.92% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently weighed in on the stock. Stifel Nicolaus set a $31.00 target price on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday. Cantor Fitzgerald restated a “hold” rating and issued a $26.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, October 3rd. Oppenheimer set a $29.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Finally, Citigroup lifted their price target on shares of Vanda Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Tuesday, October 16th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Vanda Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $27.43.

ILLEGAL ACTIVITY WARNING: This report was published by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.wkrb13.com/2018/11/08/vanda-pharmaceuticals-vnda-posts-earnings-results-beats-expectations-by-0-18-eps.html.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Read More: Why is Cost of Capital Important?

Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply